Bioxytran (BIXT) Research & Development (2021 - 2026)
Bioxytran (BIXT) posted Research & Development of $225479.0 for Q1 2026, up 11173.95% sequentially from $2000.0 in Q4 2025, and down 35.49% YoY from $349500.0 in Q1 2025.
Bioxytran (BIXT) Research & Development (2021 - 2026) Analysis & Trends
Bioxytran has reported Research & Development for 6 years, with the latest figure at $225479.0 in Q1 2026.
- Quarterly Research & Development fell 35.49% year-over-year to $225479.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $329979.0 (down 24.11% YoY) and the FY2025 annual result came in at $454000.0, up 304.14% from the prior year.
- Research & Development rose to $225479.0 in Q1 2026 per BIXT's latest filing, from $2000.0 in the prior quarter.
- Over five years, Research & Development peaked at $544438.0 in Q4 2023 and troughed at $2000.0 in Q4 2025.
- A 5-year average of $214586.2 and a median of $149638.0 in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 1194.44% in 2025, down 94.18% in 2025.
- Over 5 years, Research & Development stood at $518630.0 in 2022, then climbed by 4.98% to $544438.0 in 2023, then sank by 93.69% to $34337.0 in 2024, then sank by 94.18% to $2000.0 in 2025, then surged by 11173.95% to $225479.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $225479.0, $2000.0, and $102500.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | 255,479.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 225,479.00 |
| Dec 31, 2025 | 2,000.00 |
| Jun 30, 2025 | 102,500.00 |
| Mar 31, 2025 | 349,500.00 |
| Dec 31, 2024 | 34,337.00 |
| Sep 30, 2024 | 51,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 544,438.00 |
| Sep 30, 2023 | 316,129.00 |
| Jun 30, 2023 | 149,638.00 |
| Mar 31, 2023 | 139,004.00 |
| Dec 31, 2022 | 518,630.00 |
| Sep 30, 2022 | 475,872.00 |
| Jun 30, 2022 | 43,141.00 |
| Mar 31, 2022 | 240,125.00 |
| Dec 31, 2021 | 766,115.00 |
| Sep 30, 2021 | 181,962.00 |
| Jun 30, 2021 | 718,652.00 |
| Mar 31, 2021 | 347,033.00 |